Improving Lives Through
Innovative Diagnostic Solutions
AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions
Improving Lives Through
Innovative Diagnostic Solutions
AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions
COVID-19 TESTING
AXIM Biotech has developed a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) which are the antibodies needed to fight COVID-19 within the body.
AXIM EYE
AXIM looks to assist doctors in diagnosing dry eye disease (DED) faster and more efficiently than alternative methods.
CANCER dIAGNOSTICS
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED.
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the...
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a...